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Sensitive b-galactosidase-targeting ﬂuorescence
probe for visualizing small peritoneal metastatic
tumours in vivo
Daisuke Asanuma1,2, Masayo Sakabe2, Mako Kamiya1,3, Kyoko Yamamoto1, Jun Hiratake4, Mikako Ogawa5,w,
Nobuyuki Kosaka5,w, Peter L. Choyke5, Tetsuo Nagano6, Hisataka Kobayashi5 & Yasuteru Urano1,2,7,8
Fluorescence-guided diagnostics is one of the most promising approaches for facile detection
of cancer in situ. Here we focus on b-galactosidase, which is overexpressed in primary ovarian
cancers, as a molecular target for visualizing peritoneal metastases from ovarian cancers.
As existing ﬂuorescence probes are unsuitable, we have designed membrane-permeable
HMRef-bGal, in which the optimized intramolecular spirocyclic function affords41,400-fold
ﬂuorescence enhancement on activation. We conﬁrm that HMRef-bGal sensitively detects
intracellular b-galactosidase activity in several ovarian cancer lines. In vivo, this probe
visualizes metastases as small aso1mm in diameter in seven mouse models of disseminated
human peritoneal ovarian cancer (SHIN3, SKOV3, OVK18, OVCAR3, OVCAR4, OVCAR5 and
OVCAR8). Because of its high brightness, real-time detection of metastases with the naked
eye is possible. Endoscopic ﬂuorescence detection of metastases is also demonstrated.
The results clearly indicate preclinical potential value of the probe for ﬂuorescence-guided
diagnosis of peritoneal metastases from ovarian cancers.
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P
eritoneal metastasis1,2 is associated with a wide range of
malignancies, including ovarian, gastric and colorectal
cancers. In particular, 60%–75% of ovarian cancer
patients are diagnosed with aggressive peritoneal metastases,
mainly because early diagnosis is difﬁcult due to the
asymptomatic nature of the disease in the early stages3–5. This
is one reason why the prognosis is poor, with an expected 5-year
survival rate of 10%–20% (ref. 4). Standard therapy consists
of primary surgical cytoreduction followed by systemic
chemotherapy with paclitaxel and platinum-based agents5.
Follow-up studies have revealed that removal of peritoneal
metastases as small as o1mm in diameter improved the 5-year
survival of the patients6,7. However, efﬁcient cytoreduction is
extremely difﬁcult to achieve, owing to the poor visual contrast
between cancer and normal tissues under white light.
Consequently, ﬂuorescence-guided detection is considered one
of the most promising approaches to improve cytoreduction
efﬁcacy. 5-Aminolevulinic acid has been used in clinical studies
for diagnosis of malignancies including ovarian carcinoma
metastases8, as well as malignant gliomas9 and bladder
carcinoma10, but false positive rates were high11–13. As for
ovarian cancers, van Dam et al.14 reported intraoperative
tumour-speciﬁc imaging with a folate receptor-a-targeted
probe, demonstrating clinical potential for improved staging
and cytoreductive surgery. Recently, we also reported detection
of metastases in preclinical mouse models using a
g-glutamyltranspeptidase (GGT) activity probe, gGlu-HMRG15.
However, in two of the six mouse models tested, gGlu-HMRG
failed to visualize metastases because of their low GGT activity15.
This result prompted us to search for another reliable diagnostic
target.
Chatterjee et al.16 reported enhanced enzymatic activities of
b-galactosidase in primary ovarian cancers compared with
normal ovaries. Hence, in this study we focus on
b-galactosidase as an enzymatic target for ﬂuorescence probes,
to visualize metastases originated from ovarian cancers. However,
existing b-galactosidase-targeting ﬂuorescence probes are not
adequate for this purpose, owing to properties such as membrane
impermeability and low sensitivity. Therefore, we selected an
optimized spirocyclization strategy to design a probe, HMRef-
bGal, which enables highly sensitive detection of b-galactosidase
activity inside living cells. We validate the potential of the
synthesized probe for preclinical application and demonstrate its
suitability for in vivo laparotomic and endoscopic detection of
small peritoneal metastases in mouse models of ovarian cancer.
Results
b-Galactosidase activities in cancer cells. First, to conﬁrm
overexpression of b-galactosidase, we examined endogenous
b-galactosidase activity in several metastatic ovarian cancer cell
lines established from human ovarian cancer patients (SHIN3
(ref. 17), SKOV3 (ref. 18), OVCAR3 (ref. 19), OVCAR4,
OVCAR5, OVCAR8 and OVK18 (ref. 20)). High levels of
b-galactosidase activity were detected in these cell lines compared
with that in a non-transformed human cell line, HUVEC (human
umbilical vein endothelial cells; Fig. 1a). This result suggested that
b-galactosidase is a promising target for cancer imaging (Fig. 1b).
Molecular design and development of ﬂuorescence probes.
Therefore, we next required a suitable probe molecule. To date,
various types of b-galactosidase ﬂuorescence probes including
MUG21, FDG22, RG23 and DAOG24 have been reported.
However, these ﬁrst-generation probes are unsuitable for live-
cell imaging of intracellular b-galactosidase activity because of
their membrane impermeability. Thus, we tried our second-
generation membrane-permeable probe, TG-bGal25. However,
TG-bGal could not detect intracellular b-galactosidase activity,
because the ﬂuorescent product TG was exported from the cells
by organic anion transporters (see Supplementary Fig. 1 for
details, including the chemical structures), which are often
overexpressed in metastatic cancers and cause multidrug
resistance26. Therefore, we next tried our recently reported
HMDER-bGal27, whose ﬂuorescent product HMDER has
a net charge of zero. HMDER-bGal successfully detected
b-galactosidase activity in cultured cancer cells (see
Supplementary Fig. 2 for details, including the chemical
structures), but we found that peritoneal metastases could not
be speciﬁcally visualized, owing to high background ﬂuorescence
in a mouse tumour model.
We considered that the high background was probably due to
the pKcycl value of 6.9 for the spirocyclization equilibrium of
HMDER-bGal27, because at pH 7.4 about 25% of the probe
would be present in the ﬂuorescent open form (cf. Table 1). Thus,
to reduce the background we set out to chemically modulate the
spirocyclic equilibrium to shift the pKcycl value to B5.4. This
would imply that 499% of the probe would exist in the non-
ﬂuorescent spirocyclic form at pH 7.4. Density functional theory
calculations indicated that electron-withdrawing N-substituents
decrease the lowest unoccupied molecular orbital energy level of
the ﬂuorophore (Table 1), suggesting that the spirocyclization is
stabilized.
To examine this approach, we synthesized hydroxymethyl
rhodol (HMR) derivatives bearing b-galactoside and evaluated
their photochemical properties (see Supplementary Tables 1
and 2, and Supplementary Fig. 3 for details). The pKcycl values of
HMRet-bGal, HMRpf-bGal and HMRef-bGal were lowered in
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Figure 1 | b-Galactosidase-targeting cancer visualization strategy. (a) b-Galactosidase activity per protein abundance in lysate of SHIN3, SKOV3,
OVK18, OVCAR3, OVCAR4, OVCAR5, OVCAR8 or HUVEC cells. Data represent mean±s.d. from a single experiment in triplicate. (b) Schematic
illustration of ﬂuorescence detection of cancer cells with enhanced b-galactosidase activity using a ﬂuorescence probe.
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Table 1 | Properties of b-galactosidase ﬂuorescence probes.
R1 R2 LUMO (eV)* pKcycl Fluorescence enhancement by b-galactosidase (fold)
HMDER-bGal CH2CH3 CH2CH3 6.21 6.9 76.1 (ref. 27)
HMRet-bGal CH2CH3 H 6.28 6.3 313
HMRpf-bGal (CH2)2CF3 H 6.51 5.6 582
HMRef-bGal CH2CF3 H 6.58 4.5 1,420
HMR, hydroxymethyl rhodol; LUMO, lowest unoccupied molecular orbital.





















































































































Figure 2 | Detection of b-galactosidase activities in living ovarian cancer cells with HMRef-bGal. (a) Activation of HMRef-bGal on enzymatic reaction
with b-galactosidase. Photographs show cuvettes containing the reaction mixture irradiated with 365-nm ultraviolet light. (b) Time course of enzymatic
reaction of HMRef-bGal with b-galactosidase. b-Galactosidase (5 units) was added at 50 s. HMDER-bGal was used as a control. Probe concentrations were
0.5mM. (c) Confocal images of ovarian tumour cells treated with HMRef-bGal. Cells were incubated with 10mM HMRef-bGal for 1 h, and DIC and
ﬂuorescence images were obtained. Ex/Em¼498 nm/505–600nm. Scale bar, 100mm. (d) Fluorescence intensity of ovarian cancer cells treated with
HMRef-bGal in the presence or absence of b-GA. Fluorescence intensity of cells on a 96-well plate was measured with a plate reader (Ex/Em¼498 nm/
518 nm). Probe concentration was 10mM. Data represent means±s.e.m (n¼4).
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energy level by the N-substituents, compared with HMDER-bGal
(Table 1). Among them, HMRef-bGal (pKcycl¼ 4.5) exhibited a
minimal background signal at pH 7.4 and therefore showed an
extremely high ﬂuorescence enhancement by b-galactosidase
(41,400-fold) compared with HMDER-bGal (76-fold; Fig. 2a,b
and Table 1). In addition, the ﬂuorescent product HMRef
(Fﬂ¼ 0.78) was much brighter than HMDER (Fﬂ¼ 0.14) (ref. 27),
which would contribute to achieving high detection sensitivity of
cancers. HMRef-bGal was also expected to be cell-membrane
permeable, as the calculated logP of 2.61 obtained with the
ALOGPS 2.1 programme28 was similar to that of HMDER-bGal
(2.88) (ref. 27).
Live-cell imaging of b-galactosidase. To test the performance of
HMRef-bGal, we applied it to several cultured ovarian cancer
cells (SHIN3, SKOV3, OVK18, OVCAR3, OVCAR4, OVCAR5
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Figure 3 | Visualization of peritoneal metastases in mouse models with HMRef-bGal. (a,b) Fluorescence spectral imaging of peritoneal SHIN3
metastasis with various probes. At 5min (a) or 1 h post administration of probe (b), mice were immediately killed and imaged. In spectral unmixed images,
ﬂuorescence from the probe and autoﬂuorescence were assigned as green and grey, respectively. Scale bar, 5mm. (c) Dual-colour ﬂuorescence imaging of
metastases. Lectin-targeted staining was performed as a marker for metastases (Lectin). The mouse model was also treated for 1 h with HMRef-bGal and
imaged (Probe). The merged image was prepared by overlaying the two unmixed images. Scale bar, 5mm. (d) Fluorescence intensity on tumour nodules. In
live mouse models, tumour nodules were treated with 100mM HMRef-bGal in the presence or absence of 10mM b-GA (see Supplementary Fig. 6).
***Po0.001 by Welch’s t-test (n¼ 20 for each group). (e) Fluorescence spectral imaging of several mouse models of peritoneal metastasis at 1 h post
administration of HMRef-bGal. Arrowheads indicate metastases in the OVK18 images. Scale bar, 5mm. (f) Fluorescence endoscopy of tumours inside the
peritoneal cavity. AW, abdominal wall; Li, liver; Pc, pancreas; Sp, spleen; T, tumour. See Supplementary Video S1 online for real-time monitoring endoscopy.
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case (Fig. 2c) and the ﬂuorescence was decreased by a competitive
b-galactosidase inhibitor (b-galactosylamidine; b-GA)29 (Fig. 2d).
This result indicated that HMRef-bGal can detect intracellular
b-galactosidase activity. In addition, this probe showed almost no
cytotoxicity up to 100mM in MTT (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide) assay (Supplementary Fig. 4).
We also preliminarily evaluated its toxicity to mice. A ten times
higher dose than that employed for imaging application did not
cause lethality or signiﬁcant body weight change compared with
the control group (Supplementary Fig. 5). These results suggest
that HMRef-bGal may be safe for biological application, although
further testing would be necessary to conﬁrm this before the
probe could be used for clinical diagnosis.
Cancer diagnostic applications. As we had conﬁrmed that
HMRef-bGal can detect intracellular b-galactosidase activity,
we next examined its suitability for cancer imaging in a mouse
model of peritoneal metastasis, using SHIN3 cells. At 5min
after intraperitoneal administration of the ﬂuorescence probe,
metastases as small as o1mm in diameter inside the peritoneal
cavity were clearly and speciﬁcally visualized by HMRef-bGal, but
not by HMDER-bGal or b-galactoside-free HMRef (Fig. 3a).
Moreover, at 1 h post administration of HMRef-bGal, the ﬂuor-
escence of these nodules was enhanced so much that the tumours
could be readily distinguished with the naked eye (Fig. 3b). The
detected nodules were conﬁrmed to be ovarian metastatic cancers
on the basis of colocalization with a lectin-targeted stain30
(Fig. 3c). We also performed vital imaging and conﬁrmed that
ﬂuorescence on the metastases was suppressed by b-GA (Fig. 3d
and see Supplementary Fig. 6 for details). To check the broad
availability of this probe, mouse models prepared with other
cancer cell lines (SKOV3, OVK18, OVCAR3, OVCAR4,
OVCAR5 and OVCAR8) were tested. We found that
disseminated cancers were similarly visualized in all the models
(Fig. 3e). It is particularly noteworthy that SKOV3 and OVCAR3
metastases, which could not be visualized with our previous
GGT-targeted probe, gGlu-HMRG15, were successfully visualized
with HMRef-bGal.
Next, we performed in vivo ﬂuorescence endoscopy for
detection of metastases. An anaesthetized mouse model pre-
treated with intraperitoneal administration of HMRef-bGal was
subject to ﬂuorescence laparoscopy and the metastases were
successfully visualized (Fig. 3f and Supplementary Movie 1).
We also performed real-time ﬂuorescence-guided laparotomy
for tumour resection. One-millimetre-sized metastases were
readily recognized and resected from the peritoneal cavity
(Supplementary Movie 2 and Supplementary Fig. 7). In this trial,
the operator could recognize the location of metastases in a direct
three-dimensional view by visible ﬂuorescence of the probe. Thus,
our developed technique with HMRef-bGal was demonstrated to
have clear potential for ﬂuorescence guidance of tumor diagnosis
and surgical cytoreduction.
Discussion
In this study, we have developed a highly sensitive b-galactosidase
probe, HMRef-bGal, by chemically optimizing the intramolecular
spirocyclic function. In contrast to previously reported
probes, HMRef-bGal enabled sensitive detection of intracellular
b-galactosidase activity in living cells. Using HMRef-bGal, we
successfully imaged small peritoneal metastases in seven different
mouse models, conﬁrming the validity of b-galactosidase
as a molecular target for visualizing peritoneal metastases.
Importantly, this result also demonstrated the ability of our
technique to broaden the diagnostic spectrum for cancers by
showing that HMRef-bGal visualized SKOV3 and OVCAR3
metastases, which could not be visualized with gGlu-HMRG15.
We conﬁrmed that HMRef-bGal is available for laparotomic and
endoscopic detection of in vivo metastases. Thus, our technique
appears to have preclinical potential value for ﬂuorescence-guided
diagnosis of cancers with enhanced b-galactosidase activity. The
b-galactosidase-based diagnostic spectrum may include not only
ovarian cancer but also breast and colon cancers31, and gliomas32.
The enzymatic activation strategy is attractive for generating
highly ampliﬁed ﬂuorescence by turnover at the lesion site. We
found that metastases could be visualized in as short a period as
5min post administration. This rapid response might allow the
probe to be used not only pre-operatively but also intra-
operatively when suspicious lesions are encountered during
diagnosis and/or surgery. Furthermore, the bright and visible
signal provided by our probe would allow surgeons a direct three-
dimensional view in real time, unlike other imaging technologies
such as positron emission tomography, computed tomography
and magnetic resonance imaging. This is likely to result in
superior performance both in detection and surgical removal of
metastatic lesions, leading to improvement of cytoreduction
efﬁcacy.
In addition, chemical substitution of the b-galactoside moiety
with other glycosides has the potential to ﬂexibly target our
ﬂuorescence probe to other glycosidases that are enhanced in
various diseases, such as b-hexosaminidase in gliomas32 and lung
cancer33, a-mannosidase in breast and colon cancers31, b-N-
acetylgalactosaminidase in colon cancer34, and a-fucosidase and
b-N-acetyl-glucosaminidase in thyroid and gastric cancers35.
Thus, we believe this simple molecular design strategy is suitable
for the development of a series of highly sensitive probes for a
range of target enzymes, thereby providing sensitive diagnostics
for the corresponding diseases. Further work along this line is in
progress, aiming at realizing tailor-made diagnostic guidance.
Methods
Synthesis. For synthetic protocols of b-galactosidase ﬂuorescence probes, see the
Supplementary Information. Preparative HPLC was performed on HPLC system
composed of a pump (PU-2080, JASCO) and detector (MD-2015, JASCO), with an
Inertsil ODS-4 (10.0mm 250mm) column (GL Sciences, Inc.). NMR spectra
were recorded on a JNM-LA300 instrument (JEOL) at 300MHz for 1H NMR
and 75MHz for 13C NMR. Mass spectra were measured with a JMS-T100LC
AccuToF (JEOL).
Optical properties of probes. Ultraviolet–visible spectra were obtained on a
V-550 spectrometer (JASCO) and ﬂuorescence spectra were obtained on a FP-6500
ﬂuorescence spectrometer (JASCO). Probes were dissolved in dimethyl sulfoxide
(ﬂuorometric grade, Dojindo) to obtain stock solutions. Optical properties of
probes were examined in 200mM sodium phosphate buffer containing 0.03% (v/v)
dimethyl sulfoxide as a co-solvent. For determination of ﬂuorescence quantum
efﬁciency (Fﬂ), ﬂuorescein in 0.1M aqueous NaOH (Fﬂ¼ 0.85) was used as a
standard36.
Cell lines and culture. SHIN3 was provided by S. Imai, Nara, Japan. SKOV3 was
obtained from American Type Culture Collection. OVCAR3 and OVK18 were
obtained from RIKEN Cell Bank. OVCAR4, OVCAR5 and OVCAR8 were
provided by the Developmental Therapeutics Program, National Cancer Institute-
Frederick, NIH. All cell lines, were grown in RPMI 1640 containing 10% fetal
bovine serum (FBS), 100Uml 1 penicillin and 100 mgml 1 streptomycin (all
reagents were purchased from Life Technologies). As for preparation of tumor
models, OVK18 was grown in MEM (Life Technologies) containing 15% FBS,
100Uml 1 penicillin and 100 mgml 1 streptomycin. All cell lines were main-
tained at 37 C in 5% CO2.
Lysate preparation. Cells were cultivated on 100-mm culture dishes at 37 C in
5% CO2 in air. At B80%–90% conﬂuence, cells were washed twice with 2ml of
DPBS (Life Technologies), and 1ml of CelLyticM (Sigma) was added. Incubation
was continued for 15min at room temperature on a shaker (180 r.p.m.). The lysed
cells were collected and centrifuged for 15min at 16,000g to pellet cellular debris.
The supernatant was aliquoted into chilled test tubes and stored at  80 C.
Protein concentration in cell lysates was measured with BCA protein assay kit
(Pierce).
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Measurement of b-galactosidase activity. Experiments were performed on
96-well plates (BD Biosciences, 353219). To each well were added 10 ml of cell
lysate and 90 ml of 200mM sodium phosphate buffer (pH 5.0) containing 111 mM
TG-bGal (ﬁnal concentration 100mM). The plate was incubated at 37 C for
30min. To each well, 20ml of 1.0M aqueous NaOH was added to quench the
reaction. Fluorescence intensity (Ex/Em¼ 492 nm/509 nm) was measured with a
microplate reader (SH-8000; Corona, Electric Co., Ltd) and the background
intensity of the cell lysate-free control wells was subtracted.
Confocal imaging. Cells (4 104) were plated on eight-chamber plates (Ibidi) and
incubated with RPMI 1640 containing 10% FBS for a day. The medium was
replaced with phenol red- and serum-free RPMI 1640 containing 10 mM HMRef-
bGal. The cells were incubated for 1 h, and differential interference contrast (DIC)
and ﬂuorescence images were obtained using a Leica Application Suite Advanced
Fluorescence with a TCS SP5 X and a dry objective ( 10, numerical aperture 0.40;
Leica). The light source was a white-light laser.
Measurement of cellular ﬂuorescence intensity. Ovarian cancer cells were
plated in 96-well plates at the density of 10,000–20,000 cells per well and cultured
at 37 C in 5% CO2 in air for 1–2 days. When cells had reached B80%–90%
conﬂuence, they were rinsed with PBS (pH 7.4; Life Technologies) and to each well
was added 100ml phenol red- and serum-free RPMI 1640 containing 10 mM
HMRef-bGal, together with indicated concentrations of b-GA or vehicle alone.
After incubation at 37 C in 5% CO2 for 4 h, the ﬂuorescence intensity of each well
was measured (Ex/Em¼ 498 nm/518 nm). The background signal at 0 h incubation
was subtracted from the observed ﬂuorescence intensity.
Mouse studies. Female BALB/cAJcl-nu/nu or BALB/cA mice (6–7 weeks old)
were purchased from CLEA Japan. All experimental protocols were performed in
accordance with the policies of the Animal Ethics Committee of the University of
Tokyo.
Tumour models of peritoneal metastases. The procedure for preparation of
tumour mouse models was as previously described37,38. Brieﬂy, 1 106 cells
suspended in 300 ml of PBS (pH 7.4) were intraperitoneally injected into female
nude mice (BALB/cAJcl-nu/nu, 7–8 weeks old; day 0). In the case of the OVCAR4
models, 5 106 cells were injected. Each cell line required a different duration to
produce multiple disseminated tumours. Experiments with tumour-bearing mice
were performed around day 10 for the SHIN3 model, day 14 for the SKOV3 model,
day 21 for the OVCAR4, OVCAR5 and OVCAR8 models, and day 28 for the
OVCAR3 and OVK18 models.
In vivo spectral imaging. Mouse models of peritoneal metastasis were injected
intraperitoneally with 300 ml of 100 mM probe in PBS (pH 7.4). After 5min or 1 h,
mice were killed by exposure to CO2 and the abdominal cavities were exposed.
Fluorescence images were obtained with the Maestro In-Vivo imaging system (CRi,
Inc.). The blue–green ﬁlter setting (excitation: 470–510 nm; emission: 530 nm long
pass) was used. The tunable ﬁlter was automatically stepped in 10-nm increments
from 500 to 720 nm, while the camera sequentially captured images at each
wavelength interval. ‘Real colour images’ were constructed by combining
sequentially captured images with the corresponding colour. The spectral ﬂuor-
escence images consisting of autoﬂuorescence and probe spectra obtained with
Maestro software were left unmixed for visual assessment.
Dual-colour imaging of metastases. Thirty micrograms of Av-3ROX30 was
diluted in 300 ml of PBS (pH 7.4) and injected into SHIN3 mouse models. After 3 h,
300ml of 100mM HMRef-bGal in PBS (pH 7.4) was intraperitoneally administered
to Av-3ROX-treated mice. After 1 h, mice were killed by exposure to CO2 and the
abdominal cavity was exposed. Fluorescence images were obtained with the
Maestro In-Vivo imaging system. The blue–green ﬁlter setting (excitation:
470–510 nm; emission: 530 nm long pass) and the green ﬁlter setting (excitation:
503–555 nm; emission: 580 nm long pass) were used. The tunable ﬁlter was
automatically stepped in 10-nm increments from 500 to 800 nm. The spectral
ﬂuorescence images of autoﬂuorescence and probe spectra obtained with Maestro
software were left unmixed for visual assessment.
Fluorescence endoscopy. A clinical endoscopic system (Evis Exera-II CLV-180,
Olympus Corp.) equipped with an in-house-developed ﬂuorescence detection
system was used as described previously18. The SHIN3 mouse model of peritoneal
dissemination was subjected to intraperitoneal administration of 300 ml of 100 mM
HMRef-bGal in PBS (pH 7.4). After 1 h, the mice were anaesthetized via inhalation
of isoﬂurane (Abbott Lab.). The endoscope was inserted into the abdominal cavity
through a small abdominal incision and the abdominal cavity was inﬂated with air.
Disseminated nodules were monitored in real time in ﬂuorescence or white-light
mode. Ex/Em¼ 465–500 nm/516–556 nm.
Statistical analyses. Statistical comparisons between two samples were made
using the unpaired Welch’s t-test.
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